Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported today 20.7 month median overall survival results based on Phase II study of bavituximab in combination with docetaxel in patients with metastatic breast cancer. PPHM has been traded 3 fold of its 10day average volume as of 10:15 a.m. EST
Peregrine Pharmaceuticals Inc.
14282 Franklin Avenue
Tustin, CA 92780
United States – Map
Peregrine Pharmaceuticals (Nasdaq: PPHM) is a clinical-stage biopharmaceutical company developing and manufacturing innovative monoclonal antibody therapeutics for the treatment of cancer and viral infections. Our clinical pipeline includes bavituximab, a first-in-class monoclonal antibody with demonstrated broad-spectrum potential in cancer and viral diseases, and Cotara®, our novel brain cancer therapy. Both bavituximab and Cotara are currently in Phase II clinical development.
TUSTIN, CA — (MARKET WIRE) — 08/24/11 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 20.7 month median overall survival (OS) from a prior single-arm Phase II trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. In a separate published study(1) included in the docetaxel package insert, median OS was 11.7 months for metastatic breast cancer patients treated with docetaxel alone. Currently, Peregrine’s bavituximab is being evaluated in randomized Phase II trials in non-small cell lung cancer (NSCLC), pancreatic cancer, and hepatitis C virus (HCV), as well as in four investigator-sponsored trials (ISTs) in additional oncology indications, including HER2-negative metastatic breast cancer.